SG Americas Securities LLC Trims Holdings in Exelixis, Inc. $EXEL

SG Americas Securities LLC reduced its position in Exelixis, Inc. (NASDAQ:EXEL) by 87.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,617 shares of the biotechnology company’s stock after selling 498,036 shares during the quarter. SG Americas Securities LLC’s holdings in Exelixis were worth $3,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. increased its stake in Exelixis by 2.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after buying an additional 164,134 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Exelixis by 0.4% during the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock worth $328,196,000 after purchasing an additional 28,289 shares in the last quarter. AQR Capital Management LLC raised its stake in Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after purchasing an additional 2,926,884 shares during the period. Invesco Ltd. lifted its holdings in Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after purchasing an additional 1,596,948 shares in the last quarter. Finally, Nuveen LLC bought a new position in Exelixis in the 1st quarter worth approximately $123,310,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 0.5%

Shares of EXEL opened at $42.65 on Wednesday. The business has a fifty day moving average of $39.65 and a 200 day moving average of $40.60. The company has a market cap of $11.43 billion, a PE ratio of 20.50, a P/E/G ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total value of $1,032,400.46. Following the completion of the sale, the director owned 21,380 shares of the company’s stock, valued at $896,463.40. This trade represents a 53.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This represents a 7.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 173,005 shares of company stock valued at $7,443,678 in the last ninety days. 2.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EXEL. Oppenheimer reiterated a “market perform” rating and set a $36.00 price objective on shares of Exelixis in a research report on Wednesday, November 5th. Truist Financial cut their target price on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. TD Cowen lifted their target price on Exelixis from $44.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.45.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.